MedTrace Logo

Perioperative Symptom Study of Lung Cancer (CN-PRO-Lung 1)

NCT03341377 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 512

Last updated 2020-10-28

No results posted yet for this study

Summary

Investigators propose a multicenter prospective observational cohort study to develop and validate essential technical parameters for establishing the patient-reported outcome-based perioperative symptom management cohort in patients with lung cancer. With at least 300 patients with initial diagnosis of lung cancer and scheduled for surgery, this study will administer symptom assessments (MDASI-LC) and quality of life assessments (SIQOL) before surgery (typically within 3 days before surgery), daily after surgery (in hospital ≤ 14 days), and weekly after discharge, up to 4 weeks (±3 days) or the start day of postoperative oncologic treatment. In the upgraded research protocol, symptom and quality of life assessments (every 3 month for 1 year, every 6 month for 2-3 year, every 12 month for 4-5 year), as well as the follow-up of clinical outcomes will continue until 5 years after surgery.

Conditions

  • Patient-reported Outcomes

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    collaborator OTHER

  • Sichuan Cancer Hospital and Research Institute

    collaborator OTHER

  • Zigong No.1 Peoples Hospital

    collaborator OTHER

  • Jiangyou People's Hospital

    collaborator UNKNOWN

  • Chengdu Third People's Hospital

    collaborator UNKNOWN

  • Chengdu Seventh People's Hospital

    collaborator UNKNOWN

  • Dazhu County People's Hospital

    collaborator UNKNOWN

  • Xiaojun Yang

    lead OTHER

Principal Investigators

  • Xiaojun Yang, MD · Sichuan Cancer Hospital and Research Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-21
Primary Completion
2019-12-31
Completion
2020-01-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03341377 on ClinicalTrials.gov